Original Title: 예방적 백혈구조혈인자 사용의 한국형 권고사항

Authors' recommendations: All of the major guidelines of Europe or U.S. recommend the prophylactic use of G-CSF in patients receiving a chemotherapeutic regimen that shows a risk of febrile neutropenia of over 20%. If the risk of febrile neutropenia is between 10 and 20%, prophylaxis may be considered according to various patient-related risk factors such as age, existence of previous episodes of febrile neutropenia and the patient's performance status. Accepting these major recommendations, the committee decided to adapt the EORTC (European Organisation for Research and Treatment of Cancer) guidelines because they had won the highest scores in the domain of "rigour of development". In a retrospective chart review, the frequency of febrile neutropenia after each chemotherapeutic regimen was examined: the AC regimen (adriamycin+cyclophosphamide) in breast cancer showed 11.1% frequency; DA regimen (docetaxel+adriamycin) in breast cancer, 20.1%; CHOP regimen (cyclophosphamide+adriamycin+vincristin+prednisolone) in lymphoma, 34.8%; R-CHOP (rituximab+CHOP), 22.1%; and DFP (docetaxel+5-FU+cisplatin) in head and neck cancer, 18.4%, respectively. A prophylactic strategy showed lower costs and fewer febrile neutropenic events than with rescue strategy in neoadjuvant DA regimens.

Project Status: Completed

Year Published: 2010

URL for published report: https://www.neca.re.kr/lay1/program/S1T11C145/report/view.do?seq=35

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: South Korea

Organisation Name: National Evidence-based healthcare Collaborating Agency

Contact Address: National Evidence-based Healthcare Collaborating Agency (NECA), 3~5F Health and Welfare Social Administration B/D, 400 Neungdong-ro, Gwangjin-gu, Seoul, Korea.

Contact Name: int@neca.re.kr

Contact Email: int@neca.re.kr

Copyright: National Evidence-based Healthcare Collaborating Agency (NECA)